BCAL Diagnostics Limited
BCAL Diagnostics Limited
Your view on BDX.AX
Overview
What the company does, where it operates, and who runs it.
About BCAL Diagnostics Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Anne-Louise Arnett
- Headquarters
- 50 Clarence Street, Sydney, NSW, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Anne-Louise Arnett
- Headquarters
- 50 Clarence Street, Sydney, NSW, AU
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring.
This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BCAL Diagnostics Limited, and the rating behind it. BDX.AX last traded at AUD 0.07; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BCAL Diagnostics Limited. Starting points for BCAL Diagnostics Limited: EPS -AUD 0.02, beta 0.82 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BCAL Diagnostics Limited. BCAL Diagnostics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BCAL Diagnostics Limited. Trailing twelve-month EPS for BCAL Diagnostics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BCAL Diagnostics Limited. BCAL Diagnostics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BCAL Diagnostics Limited valued side by side against its closest peers. BCAL Diagnostics Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BCAL Diagnostics Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BCAL Diagnostics Limited executives and directors. Shares of BCAL Diagnostics Limited have traded between AUD 0.05 and AUD 0.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BCAL Diagnostics Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BCAL Diagnostics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BCAL Diagnostics Limited. Coverage tracks BCAL Diagnostics Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.